Stay updated on CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page.

Latest updates to the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedUpdated operating-status notice and version 3.2.0; removed version 3.1.0.SummaryDifference4%

- Check27 days agoChange DetectedUpdate to revision from v3.0.2 to v3.1.0 and addition of contact details for Sabine Zoechbauer-Mueller (sabine.zoechbauer-mueller@meduniwien.ac.at) with a phone-like number; effectively a version upgrade plus new contact information.SummaryDifference0.1%

- Check41 days agoChange DetectedThe page now shows Revision: v3.0.2, replacing v3.0.1, and the Back to Top element was removed.SummaryDifference0.2%

- Check49 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, names, pricing, or availability.SummaryDifference0.2%

- Check56 days agoChange DetectedThe web page has undergone significant changes, including the removal of specific location details and drug information, while also adding a facility name and a new revision number.SummaryDifference3%

- Check70 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%

Stay in the know with updates to CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page.